Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice

Madsen, Mette Simone Aae; Grønlund, Rikke Veggerby; Eid, John; Christensen-Dalsgaard, Mikkel; Sommer, Morten Otto Alexander; Rigbolt, Kristoffer; Madsen, Martin Rønn; Jelsing, Jacob; Vrang, Niels; Hansen, Henrik H.; Mikkelsen, Martin Tue

doi:10.1016/j.biopha.2020.110966

Cited by 13 publications

(13 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those modifications were reversible after starting a normal diet or one week treatment with rosiglitazone [ 78 ]. In a recently published study, diabetic B6.BKS(D)-Lepr db /J (db/db) mice that received rosiglitazone for 8 weeks developed changes in segment-specific host gene expression, without modifications of gut bacterial composition [ 79 ]. These data suggest a possible involvement of the TZDs on microbiota, but human studies regarding the impact of the drug on the microbiota in T2DM have not been reported.…”

Section: Microbiota and Therapy For Diabetes Mellitusmentioning

confidence: 99%

The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

Diabetes mellitus is considered to be a global epidemic. The combination of genetic susceptibility and an unhealthy lifestyle is considered to be the main trigger of this metabolic disorder. Recently, there has been increased interest in the roles of gut microbiota as a new potential contributor to this epidemic. Research, in recent years, has contributed to an in-depth characterization of the human microbiome and its associations with various diseases, including metabolic diseases and diabetes mellitus. It is known that diet can change the composition of gut microbiota, but it is unclear how this, in turn, may influence metabolism. The main objective of this review is to evaluate the pathogenetic association between microbiota and diabetes and to explore any new therapeutic agents, including nutraceuticals that may modulate the microbiota. We also look at several mechanisms involved in this process. There is a clear, bidirectional relationship between microbiota and diabetes. Current treatments for diabetes influence microbiota in various ways, some beneficial, but others with still unclear effects. Microbiota-aimed treatments have seen no real-world significant effects on the progression of diabetes and its complications, with more studies needed in order to find a really beneficial agent.

show abstract

Section: Microbiota and Therapy For Diabetes Mellitusmentioning

confidence: 99%

The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition to the above-mentioned antidiabetic drugs, the influence of sulfonylurea, peroxisome proliferative activated receptor (PPARG) agonists and insulin on microbiota composition and the consequent metabolic benefits has also been emphasized ( Huo et al., 2015 ; Zhang F. et al., 2019 ; Madsen et al., 2021 ). Insulin increased the abundance of Fusobacterium , which up-regulated the genes involved in triglyceride and arachidonic acid metabolism ( Zhang F. et al., 2019 ).…”

Section: Interaction Between Gut Microbiota and Antidiabetic Drugsmentioning

confidence: 99%

“…Recently, Madsen et al. revealed that rosiglitazone, a PPARG agonist, improved glucose homeostasis without influencing local gut microbiome in diabetic db/db mice by using full-length bacterial 16S rRNA sequencing ( Madsen et al., 2021 ).…”

Section: Interaction Between Gut Microbiota and Antidiabetic Drugsmentioning

confidence: 99%

Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus

Liu

Luo

Zhou

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Alterations in the composition and function of the gut microbiota have been reported in patients with type 2 diabetes mellitus (T2DM). Emerging studies show that prescribed antidiabetic drugs distort the gut microbiota signature associated with T2DM. Even more importantly, accumulated evidence provides support for the notion that gut microbiota, in turn, mediates the efficacy and safety of antidiabetic drugs. In this review, we highlight the current state-of-the-art knowledge on the crosstalk and interactions between gut microbiota and antidiabetic drugs, including metformin, α-glucosidase inhibitors, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, traditional Chinese medicines and other antidiabetic drugs, as well as address corresponding microbial-based therapeutics, aiming to provide novel preventative strategies and personalized therapeutic targets in T2DM.

show abstract

“…In diabetic db/db mice, rosiglitazone treatment significantly improved insulin sensitivity and glucose homeostasis without altering gut bacterial composition. 87 A global gene expression analysis in rosiglitazone-treated db/db mice showed substantial changes in colon and ileum, with no change in duodenum. Rosiglitazone treatment stimulated fatty acid metabolism by regulating the gene markers of intestinal fatty uptake, transport and disposal in the colon and ileum.…”

Section: Thiazolidinediones (Tzds)mentioning

confidence: 99%

“…These effects were consistent with the fact that PPAR-γ being abundantly expressed in colonic epithelial cells. 87 Another study found that Danshensu Bingpian Zhi (DBZ), a unique PPAR-γ partial agonist, prevented HFD-induced obesity and insulin resistance through modulating gut microbiota dysbiosis. 88 DBZ treatment restored intestinal barrier integrity and reversed gut dysbiosis by increasing the ratio of Bacteroidetes to Firmicutes, the relative abundance of Akkermansia, and reducing the level of HFD-induced pernicious bacteria (such as Helicobacter marmotae, Odoribacter, and Anaerotruncus).…”

Section: Thiazolidinediones (Tzds)mentioning

confidence: 99%

New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes

Chen¹,

Wang²

2021

DDDT

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a widespread metabolic disease characterized by chronic hyperglycemia. Human microbiota, which is regarded as a "hidden organ", plays an important role in the initiation and development of T2DM. In addition, antihyperglycemic agents and traditional Chinese medicine may affect the composition of gut microbiota and consequently improve glucose metabolism. However, the relationship between gut microbiota, T2DM and anti-hyperglycemic agents or traditional Chinese medicine is poorly understood. In this review, we summarized pre-clinical and clinical studies to elucidate the possible underlying mechanism. Some anti-hyperglycemic agents and traditional Chinese medicine may partly exert hypoglycemic effects by altering the gut microbiota composition in ways that reduce metabolic endotoxemia, maintain the integrity of intestinal mucosal barrier, promote the production of short-chain fatty acids (SCFAs), decrease trimethylamine-N-oxide (TMAO) and regulate bile acid metabolism. In conclusion, gut microbiota may provide some new therapeutic targets for treatment of patients with diabetes mellitus.

show abstract

Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice

Cited by 13 publications

References 71 publications

The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus

The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus

Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus

New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes

Contact Info

Product

Resources

About